KEAP1 and non-small cell lung carcinoma: In this study, we found that KEAP1/NFE2L2 mutations were associated with poorer survival in NSCLC patients receiving atezolizumab or docetaxel, while there was no significant difference in survival between atezolizumab and docetaxel.